This company listing is no longer active
Laboratorio Reig Jofre Past Earnings Performance
Past criteria checks 1/6
Laboratorio Reig Jofre's earnings have been declining at an average annual rate of -7.8%, while the Pharmaceuticals industry saw earnings growing at 13.8% annually. Revenues have been growing at an average rate of 9.1% per year. Laboratorio Reig Jofre's return on equity is 2.7%, and it has net margins of 2.1%.
Key information
-7.8%
Earnings growth rate
-14.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.0% |
| Revenue growth rate | 9.1% |
| Return on equity | 2.7% |
| Net Margin | 2.1% |
| Next Earnings Update | 26 Jul 2022 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How Laboratorio Reig Jofre makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 21 | 240 | 5 | 74 | 0 |
| 30 Sep 21 | 237 | 6 | 77 | 0 |
| 30 Jun 21 | 234 | 6 | 76 | 0 |
| 31 Mar 21 | 234 | 6 | 76 | 0 |
| 31 Dec 20 | 234 | 6 | 76 | 0 |
| 30 Sep 20 | 229 | 8 | 75 | 0 |
| 30 Jun 20 | 229 | 6 | 72 | 0 |
| 31 Mar 20 | 219 | 6 | 70 | 0 |
| 31 Dec 19 | 206 | 5 | 68 | 0 |
| 30 Sep 19 | 199 | 7 | 68 | 0 |
| 30 Jun 19 | 188 | 9 | 67 | 0 |
| 31 Mar 19 | 188 | 9 | 66 | 0 |
| 31 Dec 18 | 185 | 9 | 65 | 0 |
| 30 Sep 18 | 185 | 10 | 60 | 0 |
| 30 Jun 18 | 179 | 9 | 59 | 0 |
| 31 Mar 18 | 175 | 9 | 58 | 0 |
| 31 Dec 17 | 172 | 9 | 58 | 0 |
| 30 Sep 17 | 164 | 5 | 58 | 0 |
| 30 Jun 17 | 164 | 7 | 57 | 0 |
| 31 Mar 17 | 164 | 8 | 57 | 0 |
| 31 Dec 16 | 161 | 8 | 55 | 0 |
| 30 Sep 16 | 160 | 5 | 55 | 0 |
| 30 Jun 16 | 159 | 5 | 54 | 0 |
| 31 Mar 16 | 156 | 5 | 53 | 1 |
| 31 Dec 15 | 157 | 9 | 53 | 0 |
Quality Earnings: RJF.D has high quality earnings.
Growing Profit Margin: RJF.D's current net profit margins (2.1%) are lower than last year (2.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RJF.D's earnings have declined by 7.8% per year over the past 5 years.
Accelerating Growth: RJF.D's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: RJF.D had negative earnings growth (-10.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (8.9%).
Return on Equity
High ROE: RJF.D's Return on Equity (2.7%) is considered low.